Leukemia Diagnosis
Leukemia Diagnosis
Leukemia is unusual in that the first test is one almost everyone has had. A full blood count can suggest the diagnosis within hours, and it is often what prompts everything else. But a count cannot distinguish the types of leukemia from each other, nor from several other conditions — so it opens the question rather than answering it. The answer comes from the marrow, and then from the chromosomes and genes within those cells.
What the blood count shows
A full blood count measures the numbers of red cells, white cells and platelets, and a film report describes what the cells actually look like. Together they are the fastest route to suspecting leukemia, and the pattern matters more than any single number:
- A raised white cell count, sometimes very high, reflecting the accumulation of abnormal cells rather than a response to infection.
- A low count of normal white cells, because the abnormal cells have displaced the ones that fight infection — so the total count can be high while the working cells are few.
- Anaemia and a low platelet count, often the two together, which is what produces the tiredness and bruising.
- Abnormalities across more than one cell line, which is a pattern that points to the marrow rather than to the blood itself.
- Blast cells reported on the film — immature cells that should not be circulating, and a finding that leads directly to a marrow examination.
The film and the marrow
The blood film and the marrow examination answer different questions, and both are needed. The film shows what has escaped into the blood; the marrow shows what is happening in the place the disease actually lives.
- The blood film — a drop of blood spread on a slide and examined under the microscope, describing the size and shape of the cells, whether immature cells are present, and whether there are cells that should not be there at all.
- The marrow aspirate — a sample of fluid marrow drawn from the back of the hip bone, which gives the individual cells for counting, for flow cytometry and for chromosome and molecular testing. It is the sample that carries the diagnosis.
- The marrow trephine biopsy — a small core of intact marrow taken at the same time, showing how the cells are arranged and how full the marrow is. Some diseases are only visible in the architecture.
- The aspirate is often described as "dry" in the most crowded marrows, meaning few cells could be drawn — which is itself a finding rather than a failed test, and the reason the trephine is taken as well.
Flow cytometry: which lineage
Under the microscope, leukemias of different lineages can look similar. Flow cytometry resolves that by measuring the proteins on the surface and inside each cell, and it does so on thousands of cells at once:
- Myeloid markers — including myeloperoxidase, CD13, CD33 and CD117, identifying acute myeloid leukemia and separating its subtypes.
- Lymphoid markers — CD19, CD79a and CD10 for B-cell disease, and CD3, CD5 and CD7 for T-cell disease, identifying acute lymphoblastic leukemia and its lineage.
- Maturity markers — whether the cells express proteins that indicate maturation, which distinguishes acute from chronic disease in cases where the appearance alone is ambiguous.
- Abnormal patterns — leukemic cells often express combinations of markers that no normal cell does, and recognising that combination is often what confirms the diagnosis.
- The same panel becomes the monitoring test — the abnormal combination found at diagnosis is what a later, more sensitive test looks for when measuring residual disease.
Chromosomes and genes
The chromosome and gene results are what turn a diagnosis into a treatment plan in leukemia. Three techniques are used, and they answer slightly different questions:
- Chromosome analysis — examining the cells' chromosomes under the microscope to find gains, losses and rearrangements, which places many patients into a risk group directly.
- Fluorescence in situ hybridisation — a targeted test for a specific rearrangement, used when a particular fusion gene needs to be confirmed quickly.
- Polymerase chain reaction and sequencing — detecting fusion genes and mutations at the level of individual genes, and in the case of chronic myeloid leukemia measuring the level of the fusion gene in the blood to follow the response to treatment.
- Rapid testing for acute promyelocytic leukemia — because that subtype needs treatment started within hours, the fusion gene is confirmed by a fast method rather than waiting for full chromosome analysis.
Risk groups and measurable residual disease
Once the subtype and the molecular results are known, the disease is placed into a risk group, and treatment is chosen accordingly. Two different kinds of measurement are involved, and they are easy to confuse:
- Risk group at diagnosis — based on age, white cell count, chromosomes and mutations, and used to choose how intensive the treatment should be from the outset.
- Measurable residual disease — the amount of disease detectable by a sensitive test when the marrow looks normal under the microscope, measured at defined points during treatment.
- In acute myeloid leukemia, chromosome and gene findings place the disease in a favourable, intermediate or adverse group, which decides whether chemotherapy alone is expected to suffice or a transplant should be planned in first remission.
- In acute lymphoblastic leukemia, the same findings plus the response in the first weeks of treatment determine intensity, and identify patients for whom a transplant or cell therapy should be considered early.
- In chronic myeloid leukemia, the level of the fusion gene in the blood at fixed intervals defines whether the drug is working, whether the dose should change, and whether a deep response might eventually allow treatment to stop.
- In chronic lymphocytic leukemia, Rai or Binet stage, IGHV mutation status and TP53 or del(17p) together decide when treatment begins and whether chemotherapy has any role at all.
Turning the findings into a plan
When the subtype, the molecular results and the risk group are known, treatment can be planned. Several things should be settled before the first dose rather than discovered during it:
- A written treatment calendar — the regimen, its phases, how many cycles, and the dates at which the marrow will be reassessed.
- The response criteria stated in advance — what a good and a poor result at each assessment would lead to, including whether a transplant would be considered in first remission.
- Fertility preservation, discussed and arranged before treatment starts where the patient is of reproductive age, since some regimens affect fertility and the arrangements take time.
- Prophylaxis and support — anti-infective medication, tumour lysis prevention, transfusion arrangements, and growth factor support where the regimen requires it.
- A central venous line, planned where treatment involves repeated infusions or drugs that irritate veins.
- HLA typing for the patient and any siblings if a transplant may be needed, because identifying a donor takes weeks and is best begun early rather than at the moment it is required.
- Vaccination advice and dental review before treatment, since live vaccines are avoided afterwards and untreated dental infection becomes dangerous when counts are low.